高溢价收购关联亏损资产遭问询,康缘药业否认利益输送,能否成功跨界GLP-1赛道?

时代周报
26 Nov 2024

本文来源:时代周报 作者:杜苏敏因高溢价收购关联亏损企业,中药龙头康缘药业(600557.SH)在披露并购消息后很快受到监管部门的关注。11月25日,康缘药业发布关于回复上交所《关于江苏康缘药业股份有限公司关联交易事项的监管工作函》暨交易方案调整的公告,宣布调整交易方案,当中涉及股权和债务处理的部分有所调整,减少了前期资金支付,并在债务偿还方案中设立了对赌条款。与此同时,康缘药业还对标的公司的估值...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10